Cellular and molecular pathobiology of pulmonary arterial hypertension
Key result
PAH pathobiology stems from multifactorial vasoconstriction, vascular remodeling, and thrombosis mediated by endothelial dysfunction.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
This review highlights the complex cellular and molecular mechanisms underlying pulmonary arterial hypertension, identifying key pathways that serve as current and potential pharmacological targets.
Key Points
- To investigate the cellular and molecular mechanisms underlying pulmonary arterial hypertension (PAH).
- Analysis of cellular types involved in PAH including endothelial cells, smooth muscle cells, and fibroblasts.
- Evaluation of vascular remodeling and its association with dysfunction of potassium channels and endothelial cells.
- Genetic and pathophysiological studies focusing on mediators such as nitric oxide, prostacyclin, and endothelin.
- Vasoconstriction and enhanced vascular resistance are early components in the development of PAH.
- Endothelial dysfunction correlates with reduced vasodilator production and increased levels of vasoconstrictors such as ET-1.
- Several mediators, including cytokines and members of the transforming-growth-factor-beta superfamily, are implicated in the pathobiology of PAH.
PICO
P
Population
Pulmonary arterial hypertension
This review highlights the complex cellular and molecular mechanisms underlying pulmonary arterial hypertension, identifying key pathways that serve as current and potential pharmacological targets.
Cite This Study
Humbert et al. (2004) conducted a review in Pulmonary arterial hypertension. Pulmonary arterial hypertension is driven by a multifactorial pathobiology involving vasoconstriction, vascular remodeling, and thrombosis mediated by endothelial dysfunction and various molecular targets.